Thymosin Beta-4
Also known as TB-4, Tβ4, Timbetasin
The full 43-amino acid protein that TB-500 is derived from. Naturally occurring in most human tissues. Has a shorter half-life (~2 hours) compared to TB-500 (~2-4 days).
Regulatory Pathway
Dosing Protocol
Typical Dose
2.5-5 mg, 2-3 times weekly
Frequency
2-3 times weekly
Duration
4-8 weeks typical
Timing & Administration
Administer via Subcutaneous injection; topical for eye conditions. Frequency: 2-3 times weekly.
Popular Uses
Mechanism of Action
The primary actin-sequestering protein in mammalian cells. Regulates actin polymerization, promotes cell migration, angiogenesis, and wound healing.
Research Summary
Evidence level: clinical trials. Clinical status: Clinical trials - Phase II/III for wound healing and dry eye.
Side Effects & Safety
Important Warnings
- Contraindicated with active cancer
- Limited long-term safety data.
References
No references available.
Related Peptides
Browse all →A synthetic peptide derived from a protein found in human gastric juice. Extensive preclinical studies demonstrate efficacy in healing tendons, ligaments, muscles, and the GI tract.
View profileA synthetic 17-amino acid fragment of Thymosin Beta-4 with a longer half-life (~2-4 days) compared to the full protein (~2 hours).
View profileThe full 15-amino acid sequence containing BPC-157, derived from gastric juice with comparable healing properties.
View profile